Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy

Expert Review of Ophthalmology

Volumn 5, Issue 3, 2010, Pages 287-296

  Kurt, Rengin Aslhan ^a   Ucakhan Gündüz, Mür ^a   Gündüz, Kaan ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Allergic conjunctivitis; Antihistamines; Mast cell stabilizers; Ocular allergy; Olopatadine

Indexed keywords

ANTAZOLINE; ARTIFICIAL TEAR; AZELASTINE; BETOTASTINE; CLEMASTINE; CROMOGLYCATE DISODIUM; DESLORATADINE; EMEDASTINE; EPINASTINE; FLUOROMETHOLONE ACETATE; FLUTICASONE FUROATE; HISTAMINE; HISTAMINE H1 RECEPTOR; KETOROLAC; KETOTIFEN; LEUKOTRIENE; LEVOCABASTINE; LOTEPREDNOL ETABONATE; NEDOCROMIL; OLOPATADINE; PEMIROLAST; PHENIRAMINE; PLACEBO; THROMBOXANE;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CLINICAL EFFECTIVENESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY EYE; EYE ALLERGY; EYE TOXICITY; HUMAN; MAST CELL; NONHUMAN; NOSE ALLERGY; PERENNIAL ALLERGIC CONJUNCTIVITIS; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; STRUCTURE ACTIVITY RELATION;

EID: 77953178590     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.10.28     Document Type: Review

References (68)

1. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul. Surf. 1(3), 127-149 (2003).
2. Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol. Allergy Clin. North Am. 25(2), 263-281 (2005).
3. McGill JI. A review of the use of olopatadine in allergic conjunctivitis. Int. Ophthalmol. 25(3), 171-179 (2004).
4. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin. Exp. Immunol. 153(1), 17-21 (2008).
5. McGill J. Conjunctival cytokines in ocular allergy. Clin. Exp. Allergy 30(10), 1355-1357 (2000).
6. McGill JI, Holgate ST, Church MK, Anderson DF, Bacon A. Allergic eye disease mechanisms. Br. J. Ophthalmol. 82(10), 1203-1214 (1998).
7. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol. 115(1), 118-122 (2005).
8. Bacon AS, Ahluwalia P, Irani AM et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. 106(5), 948-954 (2000).
9. Bonini S, Bonini S, Vecchione A, Naim DM, Allansmith MR, Balsano F. Inflammatory changes in conjunctival scrapings after allergen challenge in humans. J. Allergy Clin. Immunol. 82(3 Pt 1), 462-466 (1988).
10. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin. Exp. Allergy 36(6), 777-784 (2006).
11. Anderson DF, MacLeod JD, Baddeley SM et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leukocyte infiltration. Clin. Exp. Allergy 27(9), 1060-1066 (1997).
12. Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 86(1), 34-40 (1990).
13. Miller S, Cook E, Graziano F, Spellman J, Yanni J. Human conjunctival mast cell responses in vitro to various secretagogues. Ocul. Immunol. Inflamm. 39(2), 39-49 (1996).
14. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl Acad. Sci. USA 83(12), 4464-4468 (1986).
15. Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST, Roche WR. The relative contribution of mast cell subsets to conjunctival TH2 cytokines. Invest. Ophthalmol. Vis. Sci. 42(5), 995-1001 (2001).
16. Cook EB, Stahl JL, Miller ST et al. Isolation of human conjunctival mast cells and epithelial cells: tumor necrosis factor-a from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest. Ophthalmol. Vis. Sci. 39(2), 336-343 (1998).
17. Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J. Pharmacol. 88(4), 379-397 (2002).
18. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin. Pharmacother. 5(9), 1979-1994 (2004).
19. Ohmori K, Hasegawa K, Tamura T et al. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 54(12), 809-829 (2004).
20. Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 12(4), 401-407 (1996).
21. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J. Pharmacol. Exp. Ther. 278(3), 1252-1261 (1996).
22. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunol. 79(6), 541-545 (1997).
23. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J. Ocul. Pharmacol. Ther. 12(4), 389-400 (1996).
24. Brockman H, Graff G, Spellman J, Yanni J. A comparison of the effects of olopatadine and ketotifen on model membranes. Acta Ophthalmol. Scand. Suppl. 230, 10-15 (2000).
25. Brockman HL, Momsen MM, Knudtson JR, Miller ST, Graff G, Yanni JM. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul. Immunol. Inflamm. 11(4), 247-268 (2003).
26. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann. Allergy Asthma Immunol. 87(5), 424-429 (2001).
27. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNF-a release from human conjunctival mast cells. Ann. Allergy Asthma Immunol. 84(5), 504-508 (2000).
28. Kajita J, Inano K, Fuse E, Kuwabara T, Kobayashi H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos. 30(12), 1504-1511 (2002).
29. Nonaka H, Otaki S, Ohshima E et al. Unique binding pocket for KW-4679 in the histamine H1 receptor. Eur. J. Pharmacol. 345(1), 111-117 (1998).
30. Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch. Ophthalmol. 117(5), 643-647 (1999).
31. Yanni JM, Sharif NA, Gamache DA, Miller ST, Weimer LK, Spellman JM. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol. Scand. 77(228), 33-37 (1999).
32. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006(1), 42726 (2006).
33. Lekhanont K, Park CY, Combs JC, Suwan-Apichon O, Rangsin R, Chuck RS. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. J. Ocul. Pharmacol. Ther. 23(1), 83-88 (2007). (Pubitemid 46449306)
34. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 32(6), 272-276 (2006).
35. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol. 108(1), 84-88 (1990).
36. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125(6), 797-804 (1998).
37. Leonardi AA, Abelson MB. Double-masked, randomized, placebo-controlled controlled clinical study of the mast cell stabilizing effect of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin. Ther. 25(10), 2539-2552 (2003).
38. Abelson MB, Pratt S, Mussoline JF, Townsend D. One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. Clin. Ther. 25(7), 2070-2084 (2003).
39. Deschenes J, Discepola M, Abelson MB. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta Ophthalmol. Scand. Suppl. 228, 47-52 (1999).
40. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 22(12), 1462-1472 (2000).
41. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 22(7), 826-833 (2000).
42. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked environmental study of patient preference. Curr. Med. Res. Opin. 20(8), 1167-1173 (2004).
43. Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin. Ther. 24(6), 918-929 (2002).
44. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.5% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 23(8), 1272-1280 (2001).
45. Brubaker K, Wright RC, Yerxa BR, Bayer JL. In vitro analysis of antagonism of the histamine H1 receptor by epinastine: a kinetic comparison with other marketed compounds. Presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 30 April-4 May 2006 (Abstract 4975).
46. Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival challenge model. Curr. Med. Res. Opin. 20(8), 1227-1233 (2004).
47. Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin. Ther. 28(10), 1630-1638 (2006).
48. Sumi T, Fukushima A, Sawada K et al. Evaluation of 0.1% olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis. Rinsho Ganka 62, 313-317 (2008).
49. Yaylali V, Demirlenk I, Tatlipinar S et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 81(4), 378-382 (2003).
50. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol. Scand. Suppl. 230, 52-55 (2000).
51. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin. Ther. 27(9), 1392-1402 (2005).
52. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 87(5), 549-554 (2009).
53. Dogru M, Ozmen A, Ertürk H, Sanli O, Karatas A. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: an open-label study. Clin. Ther. 24(8), 1309-1321 (2002).
54. Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin. Ther. 31(9), 1908-1921 (2009).
55. Uchio E. Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops. Clin. Ophthalmol. 2(3), 525-531 (2008).
56. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr. Med. Res. Opin. 21(9), 1377-1387 (2005).
57. Lee JS, Lee JE, Kim N, Oum BS. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther. 24(6), 557-562 (2008).
58. Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 28(9), 5 (2009).
59. Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: do they really stabilize mast cells? Curr. Opin. Allergy Clin. Immunol. 9(5), 454-465 (2009).
60. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin. Drug Metab. Toxicol. 4(4), 453-461 (2008).
61. Vogelson CT, Abelson MB, Pasquine T et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc. 25(1), 69-75 (2004).
62. Abelson MB, Gomes PJ, Pasquine T, Edwards MR, Gross RD, Robertson SM. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 28(4), 427-433 (2007).
63. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr. Eye Res. 32(12), 1017-1022 (2007).
64. Lichtenstein SJ, Pasquine TA, Edwards MR, Wells DT, Gross RD, Robertson SM. Safety and tolerability of olopatadine 0.2% in children and adolescents. J. Ocul. Pharmacol. Ther. 23(4), 366-371 (2007).
65. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr. Med. Res. Opin. 23(6), 1445-1452 (2007).
66. Rosenwasser LJ, Mahr T, Abelson MB, Gomes PJ, Kennedy K. A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. Allergy Asthma Proc. 29(6), 644-653 (2008).
67. Scoper SV, Berdy GJ, Lichtenstein SJ et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Adv. Ther. 24(6), 1221-1232 (2007).
68. Mah FS, O'Brien T, Kim T, Torkildsen G. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr. Med. Res. Opin. 24(2), 441-447 (2008).